Biocon gets three USFDA observations for Site 3 at Hyderabad; Stock under pressure

22 Jul 2022 , 09:18 AM

Biocon Limited has announced in a regulatory filing on Thursday that USFDA concluded a pre-approval inspection for Site 3, situated at Hyderabad, Telangana on July 20, 2022.

Accordingly, three observations were cited at the end of the Inspection, which we will be addressing within the stipulated time, the company said.

It  further added, Biocon stands committed to the Quality, Safety & Efficacy of its products.”

At around 9:18 AM, Biocon was trading at Rs329.15 per share down by Rs2.2 or 0.66% from its previous closing of Rs331.35 per share on the BSE.